Get the Stockscreener App
116.12
2.31%
2.61
Kymera Therapeutics Inc stock is traded at $116.12, with a volume of 296.59K.
It is up +2.31% in the last 24 hours and up +56.66% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
See More
Previous Close:
$113.51
Open:
$111.99
24h Volume:
296.59K
Relative Volume:
0.39
Market Cap:
$9.55B
Revenue:
$51.48M
Net Income/Loss:
$-315.00M
P/E Ratio:
-32.52
EPS:
-3.5708
Net Cash Flow:
$-244.00M
1W Performance:
+6.23%
1M Performance:
+56.66%
6M Performance:
+58.09%
1Y Performance:
+159.28%
1-Day Range:
$111.21
$117.08
1-Week Range:
$109.28
$118.48
52-Week Range:
$36.65
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
116.12 | 9.43B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
528.26 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.63 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.39 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.74 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.28 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-03-25 | Resumed | Guggenheim | Buy |
| Oct-24-25 | Reiterated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-18-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug - Yahoo Finance
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits
Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN
Kymera Therapeutics director sells $56.5m in shares - Investing.com UK
Kymera Therapeutics director Booth sells $3.42 million in KYMR shares - Investing.com
Kymera Therapeutics director Booth sells $3.42 million in KYMR shares By Investing.com - Investing.com India
Form 4 Kymera Therapeutics Inc For: 30 June By Investing.com - Investing.com Canada
Kymera Therapeutics director sells $56.5m in shares By Investing.com - Investing.com Canada
BofA Securities Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $125 - Moomoo
KYMR Maintained by B of A Securities -- Price Target Raised to $125 - GuruFocus
KYMR Maintained by B. Riley Securities -- Price Target Raised to $155 - GuruFocus
Form 144 KYMERA THERAPEUTICS For: 29 June By Investing.com - Investing.com Nigeria
KYMR Maintained by Truist Securities -- Price Target Raised to $136 - GuruFocus
B. Riley Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $155 - Moomoo
Kymera Therapeutics, Inc.(NasdaqGM: KYMR) added to Russell 2000 Value Benchmark - marketscreener.com
Truist raises Kymera Therapeutics price target on AD timeline By Investing.com - Investing.com Canada
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $136 - Moomoo
B. Riley Adjusts Kymera Therapeutics Price Target to $155 From $117, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics, Inc.(NasdaqGM: KYMR) added to Russell 2500 Value Benchmark - marketscreener.com
(KYMR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Form 4 Kymera Therapeutics Inc For: 26 June By Investing.com - Investing.com Nigeria
Form 144 Kymera Therapeutics For: 26 June By Investing.com - Investing.com South Africa
Form 144 KYMERA THERAPEUTICS For: 26 June By Investing.com - Investing.com Nigeria
Kymera Therapeutics affiliated funds sell $173.7m in common stock - Investing.com UK
Form 13D/A Kymera Therapeutics For: 26 June By Investing.com - Investing.com Nigeria
Kymera Therapeutics affiliated funds sell $173.7m in common stock By Investing.com - Investing.com Nigeria
Kymera climbs after expedited timeline for mid-stage eczema trial - MSN
Why Kymera Therapeutics Stock Popped This Week - The Motley Fool
KYMR Maintained by Canaccord Genuity -- Price Target Raised to $129 - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Director Bvf Partners P/Il Sells 1,578,800 Shares - MarketBeat
BVF group sells 1,630,658 Kymera (KYMR) shares in joint Form 4 - Stock Titan
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director BVF PARTNERS L P/IL - Moomoo
BVF funds sell 1.63M Kymera Therapeutics (KYMR) shares at $106.50 - Stock Titan
KYMR (NASDAQ) Form 144: Jefferies LLC files to sell 1.63M shares - Stock Titan
CCORF Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $129 - Moomoo
KYMR (NASDAQ) Form 144 shows large affiliate stock sale activity, including $57.1M trade - Stock Titan
KYMR (NASDAQ) Form 144 lists Atlas Venture planned sales totaling large share blocks - Stock Titan
Form 144 | Kymera Therapeutics(KYMR.US) Insider Proposes to Sell 6.69 Million in Common Stocks - Moomoo
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study - Yahoo Finance
Canaccord raises Kymera stock price target on trial progress - Investing.com
Thursday insider trading: CEO buys at Prospect Capital, sells at Kymera By Investing.com - Investing.com Canada
Thursday insider trading: CEO buys at Prospect Capital, sells at Kymera - Investing.com UK
Price to book forward of Kymera Therapeutics, Inc. – NASDAQ:KYMR - TradingView
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $119 to $134 - Moomoo
Truist Securities Adjusts Kymera Therapeutics PT to $136 From $116, Maintains Buy Rating - marketscreener.com
B.Riley raises Kymera Therapeutics price target on trial progress By Investing.com - Investing.com Canada
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength? - Yahoo Finance
Kymera Therapeutics, Inc. Actuals & Estimates (NASDAQ:KYMR) - TradingView
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kymera Therapeutics Inc Stock (KYMR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jacobs Bruce N. | Chief Financial Officer |
Jun 30 '26 |
Sale |
114.96 |
77,109 |
8,864,829 |
244,883 |
| Goodman Noah | Chief Business Officer |
Jul 01 '26 |
Sale |
114.29 |
3,389 |
387,329 |
47,179 |
| Mainolfi Nello | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
2.08 |
80,000 |
166,400 |
746,568 |
| Mainolfi Nello | Chief Executive Officer |
Jul 01 '26 |
Sale |
115.29 |
80,000 |
9,223,527 |
666,568 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):